Newly discovered gene variants increase risk of anxiety disorders

Several newly discovered variants of a gene increase the risk of developing anxiety disorders. A research team aims to derive new therapies from this finding which are better tailored to the individual patients.

Mental, social and inherited factors all play a role in anxiety disorders. In the journal "Molecular Psychiatry", a research team from Julius-Maximilians-Universität Würzburg (JMU) in Bavaria, Germany, describes a hitherto unknown genetic pathway for developing such diseases: They pinpointed at least four variants of the GLRB gene (glycine receptor B) as risk factors for anxiety and panic disorders. More than 5000 voluntary participants and 500 patients afflicted by panic disorder took part in the study that delivered these results.

In Germany, around 15 percent of adults suffer from anxiety and panic disorders. Some people may have an extreme fear of spiders or other objects while others have breathing difficulties and accelerated heart beat in small rooms or large gatherings of people. With some afflicted persons, the anxiety attacks occur for no apparent cause. Many patients suffer from the detrimental impacts on their everyday lives - they often have problems at work and withdraw from social contacts.

How are fear and anxiety triggered? How do anxiety disorders arise and evolve?

Scientists from Münster, Hamburg and Würzburg have looked into these questions within the scope of Collaborative Research Center (CRC) TR 58 funded by Deutsche Forschungsgemeinschaft. Their goal is to develop new therapies that are better tailored to the individual patients. Anxiety disorders can be treated with drugs and behaviour therapy for instance.

Gene triggers hyperekplexia

The discovery that different variants of the GLRB gene are associated with anxiety disorders might also contribute to the development of improved therapies. The gene had been known to the researchers for some time, albeit only in connection with a different disease:

"Some mutations of the gene cause a rare neurological disorder called hyperekplexia," explains Professor Jürgen Deckert, member of the CRC and Director of the Department of Psychiatry at the JMU University Hospital. The patients are permanently hypertonic and show pronounced startle responses, which may even cause sufferers to fall involuntarily. Similar to persons suffering from anxiety disorders, these patients develop behaviour to avoid potentially frightening situations.

The "fear network" in the brain is activated

But the GLRB gene variants that have recently been associated with anxiety and panic disorders for the first time are different from the ones described above. They occur more frequently and presumably entail less severe consequences. But they, too, trigger overshooting startle responses, and as a result may excessively activate the brain's "fear network". High-resolution images of the brain activities of study participants provided the clues for the Würzburg scientists.

"The results point to a hitherto unknown pathway of developing an anxiety disorder," Deckert says. He believes that further investigations are now necessary to determine whether these findings can be harnessed to develop new or individual therapies. For example, it is conceivable to bring the "fear network" that is misregulated by the GLRB gene back on track by administering drugs.